Lifevantage (LFVN) Current Deferred Revenue (2025 - 2026)
Lifevantage's (LFVN) quarterly Current Deferred Revenue came in at $1.1 million in Q2 2026, up 61.46% on a YoY basis from $711000.0 in Q2 2025, and up 61.46% quarter-over-quarter from $711000.0 in Q2 2025.
Powered by 
Analysis
Lifevantage (LFVN) Current Deferred Revenue (2025 - 2026) Analysis & Trends
Lifevantage (LFVN) has reported Current Deferred Revenue for 2 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Current Deferred Revenue rose 61.46% year-over-year to $1.1 million; the trailing twelve-month figure through Jun 2026 stood at $1.1 million (up 61.46% YoY), and the FY2026 full-year result was $1.1 million, up 61.46% from the prior year.
- Current Deferred Revenue grew to $1.1 million in Q2 2026 per LFVN's latest filing, from $711000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $1.1 million in Q2 2026 and bottomed at $711000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Colgate Palmolive | 70.50 Bn | 69.13 Bn | 3.30 Bn |
| 2 | Kenvue | 34.30 Bn | 33.19 Bn | 2.30 Bn |
| 3 | Kimberly Clark | 32.95 Bn | 31.99 Bn | 1.60 Bn |
| 4 | Bath & Body Works | 3.77 Bn | 2.97 Bn | 692.00 Mn |
| 5 | Prestige Consumer Healthcare | 2.29 Bn | 2.23 Bn | - |
| 6 | Perrigo | 1.91 Bn | 1.51 Bn | 313.90 Mn |
| 7 | Herbalife | 1.29 Bn | 915.90 Mn | 1.03 Bn |
| 8 | Edgewell Personal Care | 1.21 Bn | 813.03 Mn | 242.50 Mn |
| 9 | TFA Therapeutics | 1.02 Bn | 1.02 Bn | - |
| 10 | Lifevantage | 80.28 Mn | 65.36 Mn | 33.04 Mn |